Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Neoplasm, Residual"" wg kryterium: Temat


Tytuł :
Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Autorzy :
Hara R; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan. .
Onizuka M; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Kikkawa E; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Shiraiwa S; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Harada K; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Aoyama Y; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Ogiya D; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Toyosaki M; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Suzuki R; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Machida S; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Ohmachi K; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Ogawa Y; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Kawada H; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Matsushita H; Department of Laboratory Medicine, Tokai University School of Medicine, Isehara, Japan.; Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan.
Ando K; Division of Hematology/Oncology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Kanagawa, 259-1193, Japan.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Oct; Vol. 100 (10), pp. 2479-2486. Date of Electronic Publication: 2021 Jul 11.
Typ publikacji :
Journal Article
MeSH Terms :
Neoplasm, Residual/*diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis
Adult ; Female ; Humans ; Male ; Middle Aged ; Neoplasm, Residual/genetics ; Neoplasm, Residual/therapy ; Philadelphia Chromosome ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Prognosis ; Retrospective Studies ; Stem Cell Transplantation ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia.
Autorzy :
Aitken MJL; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; McGovern Medical School, UT Health Science Center-Houston, Houston, TX, USA.; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.
Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2021 Sep 03; Vol. 14 (1), pp. 137. Date of Electronic Publication: 2021 Sep 03.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Leukemia, Myeloid, Acute/*diagnosis
Neoplasm, Residual/*diagnosis
Animals ; Disease Management ; Flow Cytometry ; Hematopoietic Stem Cell Transplantation ; High-Throughput Nucleotide Sequencing ; Humans ; Immunotherapy ; Karyotyping ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/therapy ; Neoplasm, Residual/genetics ; Neoplasm, Residual/therapy ; Prognosis
Czasopismo naukowe
Tytuł :
Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis.
Autorzy :
Wu X; School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan Province, China.
Lu H; School of Medical Technology, Chengdu University of TCM, Chengdu, 611137, Sichuan Province, China; Key Laboratory of Transplant Engineering and Immunology, Regenerative Medical Center, West China Hospital, Sichuan University, Chengdu, 610041, China.
Pang T; School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610054, Sichuan Province, China.
Li X; Department of Laboratory Medicine, Hanyuan People's Hospital, Yuan, 25000, Sichuan, China.
Luo H; School of Laboratory Medicine, Zunyi Medical University, Zunyi, 563000, Guizhou, China.
Tan H; Department of General Surgery, Chengdu Integrated TCM&Western Medicine Hospital (Chengdu First People's Hospital), No.18 Vientiane North Road, Hi-tech Zone, Chengdu, 610041, China. Electronic address: .
Liu S; Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, No.32 West Second Section First Ring Road, Chengdu, 610072, Sichuan, China. Electronic address: .
Pokaż więcej
Źródło :
Leukemia research [Leuk Res] 2021 Sep; Vol. 108, pp. 106605. Date of Electronic Publication: 2021 May 03.
Typ publikacji :
Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Lymphoma, Mantle-Cell/*mortality
Neoplasm, Residual/*mortality
Humans ; Lymphoma, Mantle-Cell/pathology ; Lymphoma, Mantle-Cell/therapy ; Neoplasm, Residual/pathology ; Neoplasm, Residual/therapy ; Prognosis ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Autorzy :
Wang H; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China.; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
Li XQ; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China.; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.
Chu TT; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China.; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.
Han SY; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China.; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.
Qi JQ; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China.; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
Tang YQ; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China.; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.
Qiu HY; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China.; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.
Fu CC; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China.; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.
Tang XW; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China.; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.
Ruan CG; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China.; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China.; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China.; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.
Wu DP; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China. .; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China. .; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. .; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China. .
Han Y; Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, No. 188 Shizi Street, Suzhou, 215000, China. .; Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Suzhou, China. .; Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou, China. .; State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Sep; Vol. 147 (9), pp. 2659-2670. Date of Electronic Publication: 2021 Feb 07.
Typ publikacji :
Journal Article
MeSH Terms :
Mutation*
Tandem Repeat Sequences*
CCAAT-Enhancer-Binding Proteins/*genetics
Hematopoietic Stem Cell Transplantation/*mortality
Leukemia, Myeloid, Acute/*mortality
Neoplasm, Residual/*mortality
fms-Like Tyrosine Kinase 3/*genetics
Adolescent ; Adult ; Aged ; Cytogenetics ; Female ; Follow-Up Studies ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/pathology ; Leukemia, Myeloid, Acute/therapy ; Male ; Middle Aged ; Neoplasm, Residual/genetics ; Neoplasm, Residual/pathology ; Neoplasm, Residual/therapy ; Prognosis ; Retrospective Studies ; Risk Factors ; Survival Rate ; Transplantation, Homologous ; Young Adult
Czasopismo naukowe
Tytuł :
Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome.
Autorzy :
Taga T; Department of Pediatrics, Shiga University of Medical Science, Otsu, Japan. .
Tanaka S; Department of Clinical Biostatistics, Graduate School of Medicine Kyoto University, Kyoto, Japan.
Hasegawa D; Department of Pediatrics, St Luke's International Hospital, Tokyo, Japan.
Terui K; Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Toki T; Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Iwamoto S; Department of Pediatrics, Mie University Graduate School of Medicine, Tsu, Japan.
Hiramatsu H; Department of Pediatrics, Graduate School of Medicine Kyoto University, Kyoto, Japan.
Miyamura T; Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan.
Hashii Y; Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine, Suita, Japan.
Moritake H; Division of Pediatrics, Department of Reproductive and Developmental Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
Nakayama H; Department of Pediatrics, Kyushu Cancer Center, Fukuoka, Japan.
Takahashi H; Department of Pediatrics, Toho University, Tokyo, Japan.
Shimada A; Department of Pediatrics, Okayama University Graduate School of Medicine, Okayama, Japan.
Taki T; Laboratory of Clinical Hematology, Department of Medical Technology, Kyorin University Faculty of Health Sciences, Mitaka, Japan.
Ito E; Department of Pediatrics, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
Hama A; Department of Hematology and Oncology, Children's Medical Center, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Ito M; Department of Pathology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Koh K; Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan.
Hasegawa D; Department of Hematology/Oncology, Hyogo Children's Medical Center, Kobe, Japan.
Saito AM; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Adachi S; Human Health Science, Kyoto University, Kyoto, Japan.
Tomizawa D; Division of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2508-2516. Date of Electronic Publication: 2021 Feb 15.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Down Syndrome/*complications
Flow Cytometry/*methods
GATA1 Transcription Factor/*genetics
Hematopoietic Stem Cell Transplantation/*adverse effects
Leukemia, Myeloid, Acute/*pathology
Neoplasm, Residual/*pathology
Adolescent ; Biomarkers, Tumor/genetics ; Child ; Child, Preschool ; Combined Modality Therapy ; Female ; Follow-Up Studies ; Humans ; Infant ; Infant, Newborn ; Leukemia, Myeloid, Acute/therapy ; Male ; Neoplasm, Residual/etiology ; Neoplasm, Residual/metabolism ; Polymerase Chain Reaction/methods ; Prognosis ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Pediatric Tongue Base Suspension With Fluoroscopic Guidance.
Autorzy :
Valika T; Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, U.S.A.; Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, U.S.A.
Maksimoski M; Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, U.S.A.
Maurrasse S; Division of Pediatric Otolaryngology-Head and Neck Surgery, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, U.S.A.; Department of Otolaryngology-Head and Neck Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, U.S.A.; Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, Yale School of Medicine, New Haven, Connecticut, U.S.A.
Pokaż więcej
Źródło :
The Laryngoscope [Laryngoscope] 2021 Sep; Vol. 131 (9), pp. 2112-2114. Date of Electronic Publication: 2021 Feb 15.
Typ publikacji :
Journal Article; Video-Audio Media
MeSH Terms :
Fluoroscopy/*methods
Neoplasm, Residual/*surgery
Sleep Apnea, Obstructive/*surgery
Suture Techniques/*instrumentation
Tongue/*surgery
Child ; Follow-Up Studies ; Glossoptosis/complications ; Humans ; Neoplasm, Residual/diagnosis ; Neoplasm, Residual/etiology ; Polysomnography/standards ; Postoperative Complications/epidemiology ; Postoperative Complications/pathology ; Sleep Apnea, Obstructive/diagnosis ; Sleep Apnea, Obstructive/etiology ; Suture Techniques/adverse effects ; Suture Techniques/trends ; Tongue/physiopathology ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer.
Autorzy :
Zhao D; Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Yue P; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan nanli 17, Chaoyang District, Beijing, 100021, China.
Wang T; Department of Pancreatic and Gastric Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
Wang P; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan nanli 17, Chaoyang District, Beijing, 100021, China.
Song Q; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan nanli 17, Chaoyang District, Beijing, 100021, China.
Wang J; Jinchenjunchuang Clinical Laboratory, Hangzhou, Zhejiang, China.
Jiao Y; State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Panjiayuan nanli 17, Chaoyang District, Beijing, 100021, China. .
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2021 Oct 12; Vol. 14 (1), pp. 164. Date of Electronic Publication: 2021 Oct 12.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Neoplasm, Residual/*pathology
Peritoneal Neoplasms/*secondary
Stomach Neoplasms/*pathology
Humans ; Neoplasm Metastasis/diagnosis ; Neoplasm Metastasis/pathology ; Neoplasm, Residual/diagnosis ; Peritoneal Lavage ; Peritoneal Neoplasms/diagnosis ; Prognosis ; Prospective Studies ; Stomach Neoplasms/diagnosis
Raport
Tytuł :
Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL.
Autorzy :
Das N; Laboratory Oncology Unit, Dr B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India.
Gupta R; Laboratory Oncology Unit, Dr B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India. .
Gupta SK; Laboratory Oncology Unit, Dr B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India.
Bakhshi S; Department of Medical Oncology, Dr B.R. Ambedkar IRCH, AIIMS, New Delhi, India.
Seth R; Department of Pediatrics, AIIMS, New Delhi, India.
Kumar C; Laboratory Oncology Unit, Dr B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India.
Rai S; Laboratory Oncology Unit, Dr B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India.
Singh S; Laboratory Oncology Unit, Dr B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India.
Prajapati VK; Laboratory Oncology Unit, Dr B.R. Ambedkar IRCH, All India Institute of Medical Sciences (AIIMS), New Delhi, 110029, India.
Gogia A; Department of Medical Oncology, Dr B.R. Ambedkar IRCH, AIIMS, New Delhi, India.
Sahoo RK; Department of Medical Oncology, Dr B.R. Ambedkar IRCH, AIIMS, New Delhi, India.
Sharma A; Department of Medical Oncology, Dr B.R. Ambedkar IRCH, AIIMS, New Delhi, India.
Kumar L; Department of Medical Oncology, Dr B.R. Ambedkar IRCH, AIIMS, New Delhi, India.
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2021 Oct; Vol. 100 (10), pp. 2487-2500. Date of Electronic Publication: 2021 Jul 08.
Typ publikacji :
Journal Article
MeSH Terms :
Neoplasm, Residual/*diagnosis
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis
Antigens, CD/analysis ; Flow Cytometry ; Humans ; Immunophenotyping ; Neoplasm, Residual/therapy ; Neprilysin/analysis ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/therapy ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Autorzy :
Michels N; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands; Department of Pediatric Oncology and Hematology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, Netherlands.
Boer JM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands.
Enshaei A; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Sutton R; School of Women and Children's Health, University of New South Wales Medicine, Randwick, NSW, Australia; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia.
Heyman M; Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden; Department of Paediatric Oncology, Karolinska University Hospital, Stockholm, Sweden.
Ebert S; Clinic of Pediatric Hematology and Oncology, University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany.
Fiocco M; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Mathematical Institute, Leiden University, Leiden, Netherlands; Department of Biomedical Data Sciences, Medical Statistics Section, Leiden University Medical Center, Leiden, Netherlands; Dutch Childhood Oncology Group, Utrecht, Netherlands.
de Groot-Kruseman HA; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Dutch Childhood Oncology Group, Utrecht, Netherlands.
van der Velden VHJ; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands.
Barbany G; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden.
Escherich G; Clinic of Pediatric Hematology and Oncology, University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany.
Vora A; Department of Haematology, Great Ormond Street Hospital, London, UK.
Trahair T; School of Women and Children's Health, University of New South Wales Medicine, Randwick, NSW, Australia; Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales, Sydney, NSW, Australia; Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.
Dalla-Pozza L; Cancer Centre for Children, The Children's Hospital at Westmead, Westmead, NSW, Australia.
Pieters R; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Dutch Childhood Oncology Group, Utrecht, Netherlands.
Zur Stadt U; Clinic of Pediatric Hematology and Oncology, University Medical Centre, Hamburg-Eppendorf, Hamburg, Germany.
Schmiegelow K; Department of Pediatrics and Adolescent Medicine, University Hospital Rigshospitalet, Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark.
Moorman AV; Leukaemia Research Cytogenetics Group, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK.
Zwaan CM; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology and Hematology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, Netherlands. Electronic address: .
den Boer ML; Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands; Department of Pediatric Oncology and Hematology, Erasmus Medical Center-Sophia Children's Hospital, Rotterdam, Netherlands.
Pokaż więcej
Źródło :
The Lancet. Haematology [Lancet Haematol] 2021 Oct; Vol. 8 (10), pp. e700-e710.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Gene Deletion*
Neoplasm, Residual*
Down Syndrome/*complications
Ikaros Transcription Factor/*deficiency
Ikaros Transcription Factor/*genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*genetics
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Adolescent ; Child ; Child, Preschool ; Cohort Studies ; Disease-Free Survival ; Female ; Humans ; Male ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications
Czasopismo naukowe
Tytuł :
Flow Cytometry Is More Sensitive Than Fluorescence In Situ Hybridization for Detecting Minimal Residual Disease.
Autorzy :
Ng DP
Miles RR; University of Utah and ARUP Laboratories Salt Lake City, UT, USA.
Andersen EF; University of Utah and ARUP Laboratories Salt Lake City, UT, USA.
Toydemir RM; University of Utah and ARUP Laboratories Salt Lake City, UT, USA.
Pokaż więcej
Źródło :
American journal of clinical pathology [Am J Clin Pathol] 2021 Sep 08; Vol. 156 (4), pp. 715-716.
Typ publikacji :
Letter; Comment
MeSH Terms :
Neoplasm, Residual*
Flow Cytometry ; Humans ; Immunophenotyping ; In Situ Hybridization, Fluorescence
Opinia redakcyjna
Tytuł :
Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma.
Autorzy :
Mohan M; Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Szabo A; Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Yarlagadda N; Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Gundarlapalli S; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Thanendrarajan S; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Kendrick S; Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Schinke C; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Alapat D; Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Sawyer J; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Tian E; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Tricot G; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
van Rhee F; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Zangari M; Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2021 Sep 01; Vol. 96 (9), pp. E341-E344. Date of Electronic Publication: 2021 Jun 29.
Typ publikacji :
Letter
MeSH Terms :
Bone Marrow/*pathology
Multiple Myeloma/*pathology
Neoplasm, Residual/*pathology
Aged ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Neoplasm, Residual/diagnosis ; Prognosis ; Survival Analysis
Opinia redakcyjna
Tytuł :
Co-culture model of B-cell acute lymphoblastic leukemia recapitulates a transcription signature of chemotherapy-refractory minimal residual disease.
Autorzy :
Rellick SL; Department of Microbiology, Immunology and Cell Biology, West Virginia University School of Medicine, 1 Medical Center Drive, Morgantown, WV, 26506, USA.; West Virginia University Cancer Institute, Morgantown, WV, 26506, USA.
Hu G; Department of Microbiology, Immunology and Cell Biology, West Virginia University School of Medicine, 1 Medical Center Drive, Morgantown, WV, 26506, USA.; Bioinformatics Core, West Virginia University, Morgantown, WV, 26506, USA.; West Virginia Clinical and Translational Science Institute, Morgantown, WV, 26506, USA.
Piktel D; Department of Microbiology, Immunology and Cell Biology, West Virginia University School of Medicine, 1 Medical Center Drive, Morgantown, WV, 26506, USA.; West Virginia University Cancer Institute, Morgantown, WV, 26506, USA.
Martin KH; Department of Microbiology, Immunology and Cell Biology, West Virginia University School of Medicine, 1 Medical Center Drive, Morgantown, WV, 26506, USA.; West Virginia University Cancer Institute, Morgantown, WV, 26506, USA.
Geldenhuys WJ; Department of Pharmaceutical Sciences, West Virginia University School of Pharmacy, Morgantown, WV, 26506, USA.
Nair RR; Department of Microbiology, Immunology and Cell Biology, West Virginia University School of Medicine, 1 Medical Center Drive, Morgantown, WV, 26506, USA.; West Virginia University Cancer Institute, Morgantown, WV, 26506, USA.
Gibson LF; Department of Microbiology, Immunology and Cell Biology, West Virginia University School of Medicine, 1 Medical Center Drive, Morgantown, WV, 26506, USA. .; West Virginia University Cancer Institute, Morgantown, WV, 26506, USA. .
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2021 Aug 04; Vol. 11 (1), pp. 15840. Date of Electronic Publication: 2021 Aug 04.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Transcriptome*
Antineoplastic Agents/*pharmacology
Drug Resistance, Neoplasm/*genetics
Mesenchymal Stem Cells/*pathology
Neoplasm, Residual/*pathology
Osteoblasts/*pathology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*pathology
Coculture Techniques ; Humans ; Mesenchymal Stem Cells/drug effects ; Mesenchymal Stem Cells/metabolism ; Neoplasm, Residual/drug therapy ; Neoplasm, Residual/genetics ; Osteoblasts/drug effects ; Osteoblasts/metabolism ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; RNA-Seq
Czasopismo naukowe
Tytuł :
Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
Autorzy :
Esteve J; Hematology Department, Hospital Clínic of Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain. .
Giebel S; Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Institute-Oncology Center, Gliwice Branch, Gliwice, Poland. .
Labopin M; EBMT Paris Study Office, Department of Hematology and Cell Therapy, Hôpital Saint-Antoine, Paris, France.
Czerw T; Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Institute-Oncology Center, Gliwice Branch, Gliwice, Poland.
Wu D; Department of Hematology, The First Hospital Affiliated to Soochow University, Suzhou, China.
Volin L; Stem Cell Transplantation Unit, Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
Socié G; Division of Hematology, Hospital St Louis and University Paris, Paris, France.
Yakoub-Agha I; Hôpital Claude Huriez, Lille, France.
Maertens J; University Hospital Gasthuisberg, Leuven, Belgium.
Cornelissen JJ; Erasmus MC-Daniel den Hoed Cancer Centre, Rotterdam, The Netherlands.
Pigneux A; CHU Bordeaux, Hôpital Haut-Lévêque, Pessac, France.
Shimoni A; Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Schwerdtfeger R; Center for Hematopoietic Cell Transplantation, Deutsche Klinik für Diagnostik Helios Klinik, Wiesbaden, Germany.
Labussière-Wallet H; Hôpital Edouard Herriot, Lyon, France.
Russell N; Nottingham University Hospitals and University of Nottingham, Nottingham, UK.
Schattenberg A; Department of Hematology, Nijmegen Medical Centre, Radboud University, Nijmegen, The Netherlands.
Chevallier P; Department d'Hematologie, CHU Nantes, Nantes, France.
Koza V; Charles University Hospital, Pilsen, Czech Republic.
Foà R; Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.
Schmid C; Department of Hematology and Oncology, Augsburg University Hospital, Augsburg, Germany.
Peric Z; University Hospital Center Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia.
Mohty M; EBMT Paris Study Office, Department of Hematology and Cell Therapy, Hôpital Saint-Antoine, Paris, France.; Department of Hematology, Hospital Saint Antoine, Paris, France.
Nagler A; EBMT Paris Study Office, Department of Hematology and Cell Therapy, Hôpital Saint-Antoine, Paris, France.; Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Pokaż więcej
Źródło :
Leukemia [Leukemia] 2021 Aug; Vol. 35 (8), pp. 2232-2242. Date of Electronic Publication: 2021 Feb 04.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Chromosomes, Human, Pair 11/*genetics
Chromosomes, Human, Pair 4/*genetics
DNA-Binding Proteins/*genetics
Hematopoietic Stem Cell Transplantation/*methods
Histone-Lysine N-Methyltransferase/*genetics
Myeloid-Lymphoid Leukemia Protein/*genetics
Neoplasm, Residual/*therapy
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Transcriptional Elongation Factors/*genetics
Adult ; DNA-Binding Proteins/metabolism ; Female ; Follow-Up Studies ; Histone-Lysine N-Methyltransferase/metabolism ; Humans ; Male ; Myeloid-Lymphoid Leukemia Protein/metabolism ; Neoplasm, Residual/genetics ; Neoplasm, Residual/pathology ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Prognosis ; Remission Induction ; Retrospective Studies ; Survival Rate ; Transcriptional Elongation Factors/metabolism ; Translocation, Genetic ; Transplantation Conditioning ; Transplantation, Homologous
Czasopismo naukowe
Tytuł :
Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
Autorzy :
Fei Z; Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Medical University, Fuma Road, Fuzhou, 350014, Fujian, People's Republic of China.
Xu T; Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Medical University, Fuma Road, Fuzhou, 350014, Fujian, People's Republic of China.
Qiu X; Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Medical University, Fuma Road, Fuzhou, 350014, Fujian, People's Republic of China.
Li M; Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Medical University, Fuma Road, Fuzhou, 350014, Fujian, People's Republic of China.
Chen T; Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Medical University, Fuma Road, Fuzhou, 350014, Fujian, People's Republic of China.
Li L; Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Medical University, Fuma Road, Fuzhou, 350014, Fujian, People's Republic of China.
Huang C; Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Medical University, Fuma Road, Fuzhou, 350014, Fujian, People's Republic of China.
Chen C; Department of Radiation Oncology, Fujian Medical University Cancer Hospital and Fujian Cancer Hospital, Fujian Medical University, Fuma Road, Fuzhou, 350014, Fujian, People's Republic of China. .
Pokaż więcej
Źródło :
Journal of cancer research and clinical oncology [J Cancer Res Clin Oncol] 2021 Jul; Vol. 147 (7), pp. 2047-2055. Date of Electronic Publication: 2021 Jan 03.
Typ publikacji :
Journal Article
MeSH Terms :
Epstein-Barr Virus Infections/*complications
Nasopharyngeal Carcinoma/*radiotherapy
Nasopharyngeal Neoplasms/*radiotherapy
Neoplasm, Residual/*radiotherapy
Radiotherapy, Intensity-Modulated/*mortality
Adolescent ; Adult ; Aged ; DNA, Viral/analysis ; Disease Progression ; Dose-Response Relationship, Radiation ; Epstein-Barr Virus Infections/virology ; Female ; Follow-Up Studies ; Herpesvirus 4, Human/genetics ; Herpesvirus 4, Human/isolation & purification ; Humans ; Male ; Middle Aged ; Nasopharyngeal Carcinoma/pathology ; Nasopharyngeal Carcinoma/virology ; Nasopharyngeal Neoplasms/pathology ; Nasopharyngeal Neoplasms/virology ; Neoplasm, Residual/pathology ; Neoplasm, Residual/virology ; Prognosis ; Retreatment ; Retrospective Studies ; Survival Rate ; Young Adult
Czasopismo naukowe
Tytuł :
How I investigate minimal residual disease in acute lymphoblastic leukemia.
Autorzy :
Correia RP; Clinical Pathology Laboratory, Flow Cytometry Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Bento LC; Clinical Pathology Laboratory, Flow Cytometry Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.
de Sousa FA; Clinical Pathology Laboratory, Flow Cytometry Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Barroso RS; Clinical Pathology Laboratory, Flow Cytometry Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Campregher PV; Clinical Pathology Laboratory, Molecular Genetics Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.
Bacal NS; Clinical Pathology Laboratory, Flow Cytometry Division, Hospital Israelita Albert Einstein, São Paulo, Brazil.; Centro de Hematologia de São Paulo, São Paulo, Brazil.
Pokaż więcej
Źródło :
International journal of laboratory hematology [Int J Lab Hematol] 2021 Jun; Vol. 43 (3), pp. 354-363. Date of Electronic Publication: 2021 Jan 10.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Neoplasm, Residual/*diagnosis
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*diagnosis
Animals ; B-Lymphocytes/pathology ; Flow Cytometry/methods ; Gene Fusion ; Gene Rearrangement ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Immunoglobulin G/genetics ; Neoplasm, Residual/genetics ; Neoplasm, Residual/pathology ; Polymerase Chain Reaction/methods ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Receptors, Antigen, T-Cell/genetics ; T-Lymphocytes/pathology
Czasopismo naukowe
Tytuł :
Clinical values of gene alterations as marker of minimal residual disease in non-M3 acute myeloid leukemia.
Autorzy :
Yu T; Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Chi J; Center for the Study of Hematological Malignancies, Nicosia, Cyprus.
Wang L; Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 848-859.
Typ publikacji :
Journal Article
MeSH Terms :
Leukemia, Myeloid, Acute/*genetics
Neoplasm, Residual/*genetics
Biomarkers, Tumor/analysis ; Biomarkers, Tumor/genetics ; Flow Cytometry ; High-Throughput Nucleotide Sequencing ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Neoplasm, Residual/diagnosis ; Polymerase Chain Reaction ; Prognosis
Czasopismo naukowe
Tytuł :
Impact of pre-transplantation minimal residual disease (MRD) on the outcome of Allogeneic hematopoietic stem cell transplantation for acute leukemia.
Autorzy :
Shen X; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Pan J; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Qi C; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Feng Y; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Wu H; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Qian S; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Lu H; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Chen L; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Li J; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Miao K; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Qiu H; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Zhu H; Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, People's Republic of China.; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, People's Republic of China.
Pokaż więcej
Źródło :
Hematology (Amsterdam, Netherlands) [Hematology] 2021 Dec; Vol. 26 (1), pp. 295-300.
Typ publikacji :
Journal Article
MeSH Terms :
Hematopoietic Stem Cell Transplantation*/adverse effects
Leukemia, Myeloid, Acute/*therapy
Neoplasm, Residual/*therapy
Adolescent ; Adult ; Female ; Graft vs Host Disease/etiology ; Humans ; Leukemia, Myeloid, Acute/diagnosis ; Male ; Middle Aged ; Neoplasm, Residual/diagnosis ; Prognosis ; Transplantation, Homologous/adverse effects ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study.
Autorzy :
Chauhan PS; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Chen K; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Babbra RK; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Feng W; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Pejovic N; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Nallicheri A; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Harris PK; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Dienstbach K; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, United States of America.
Atkocius A; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, United States of America.
Maguire L; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, United States of America.
Qaium F; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Szymanski JJ; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Baumann BC; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, United States of America.
Ding L; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, United States of America.; Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, United States of America.; McDonnell Genome Institute, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Cao D; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Reimers MA; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, United States of America.
Kim EH; Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, United States of America.; Division of Urology, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Smith ZL; Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, United States of America.; Division of Urology, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, United States of America.
Arora VK; Division of Medical Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, United States of America.
Chaudhuri AA; Division of Cancer Biology, Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri, United States of America.; Department of Genetics, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Division of Biology and Biomedical Sciences, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Department of Biomedical Engineering, Washington University School of Medicine, St. Louis, Missouri, United States of America.; Department of Computer Science and Engineering, Washington University in St. Louis, St. Louis, Missouri, United States of America.
Pokaż więcej
Źródło :
PLoS medicine [PLoS Med] 2021 Aug 31; Vol. 18 (8), pp. e1003732. Date of Electronic Publication: 2021 Aug 31 (Print Publication: 2021).
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*analysis
Cystectomy/*statistics & numerical data
DNA, Neoplasm/*analysis
Neoplasm, Residual/*diagnosis
Urinary Bladder Neoplasms/*diagnosis
Urine/*chemistry
Aged ; Aged, 80 and over ; Cohort Studies ; Female ; Humans ; Male ; Middle Aged ; Missouri ; Neoplasm Invasiveness/pathology ; Neoplasm, Residual/etiology ; Progression-Free Survival ; Urinary Bladder Neoplasms/etiology
Czasopismo naukowe
Tytuł :
Making clinical decisions based on measurable residual disease improves the outcome in multiple myeloma.
Autorzy :
Martinez-Lopez J; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain. .; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA. .
Alonso R; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
Wong SW; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA.
Rios R; Hematology Department, Hospital Virgen de Las Nieves, Granada, Spain.
Shah N; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA.
Ruiz-Heredia Y; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
Sanchez-Pina JM; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
Sanchez R; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
Bahri N; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA.
Zamanillo I; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
Poza M; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
Buenache N; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
Encinas C; Hematology Department, Hospital General Univesitario Gregorio Marañon, Madrid, Spain.
Juarez L; Hematology Department, Hospital General Univesitario Gregorio Marañon, Madrid, Spain.
Miras F; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
Collado L; Medicine Department, Complutense University, Madrid, Spain.
Barrio S; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
Martin T; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA.
Cedena MT; Hematology Department, Hospital 12 de Octubre i+12, CNIO, Complutense University, Madrid, Spain.
Wolf J; Department of Medicine, Division of Hematology-Oncology, University of California San Francisco, San Francisco, USA.
Pokaż więcej
Źródło :
Journal of hematology & oncology [J Hematol Oncol] 2021 Aug 17; Vol. 14 (1), pp. 126. Date of Electronic Publication: 2021 Aug 17.
Typ publikacji :
Letter; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Multiple Myeloma/*diagnosis
Neoplasm, Residual/*diagnosis
Clinical Decision-Making ; Disease Management ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/therapy ; Neoplasm, Residual/therapy ; Prognosis ; Retrospective Studies ; Treatment Outcome
Raport
Tytuł :
Predictive impact of residual disease detected using multiparametric flow cytometry on risk stratification of paediatric acute myeloid leukaemia with normal karyotype.
Autorzy :
Zeng HM; Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.
Hu GH; Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Lu AD; Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.
Jia YP; Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.
Zuo YX; Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.
Zhang LP; Department of Pediatrics, Peking University People's Hospital, Peking University, Beijing, China.
Pokaż więcej
Źródło :
International journal of laboratory hematology [Int J Lab Hematol] 2021 Aug; Vol. 43 (4), pp. 752-759. Date of Electronic Publication: 2021 May 14.
Typ publikacji :
Journal Article
MeSH Terms :
Leukemia, Myeloid, Acute/*diagnosis
Neoplasm, Residual/*diagnosis
Adolescent ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Child ; Child, Preschool ; Female ; Flow Cytometry ; Humans ; Induction Chemotherapy ; Infant ; Karyotype ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Male ; Neoplasm, Residual/genetics ; Prognosis ; Proportional Hazards Models
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies